Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study

Aleksandra Opinc1 · Joanna Sarnik1 · Olga Brzezińska1 · Marcin Makowski2 · Anna Lewandowska-Polak1 · Joanna Makowska1

Received: 20 December 2019 / Accepted: 13 March 2020 / Published online: 28 March 2020 © The Author(s) 2020

Abstract

Idiopathic inflammatory myopathies (IIM) are rare connective tissue diseases, which can lead to internal organ involvement. IL-33/ST2 pathway is involved in the pathogenesis of numerous diseases including autoimmune disorders. IL-33 fulfils cardioprotective function, while soluble ST2 (sST2) is a decoy receptor that reduces protective impact of IL-33. The aim of the study was to evaluate the concentrations of sST2 and IL-33 in sera of patients with IIM and evaluate its associations with the clinical course of the disease. Patients with IIM as well as age- and sex-matched healthy controls were recruited. Concentrations of sST2 and IL-33 were assessed with ELISA in sera of both patients and controls. Patients were asked to fill in the questionnaires concerning clinical symptoms and physical functioning. Concentrations of sST2 and IL-33 were correlated with the results of laboratory tests and clinical symptoms. Concentrations of sST2 were significantly higher in IIM group than in healthy subjects (median sST2 in IIM 26.51 vs in healthy controls 21.39; \(p = 0.03\)). In the majority of patients, IL-33 concentrations did not exceed the detection limit. Anti-SRP-positive patients presented significantly higher concentrations of sST2 as compared to anti-SRP-negative patients (\(p = 0.04\)). In patients with anti-Ro52 antibodies, sST2 concentrations were significantly lower than in anti-Ro52-negative patients (\(p = 0.02\)). Concentrations of sST2 correlated with the degree of disability evaluated with Health Assessment Questionnaire. sST2 is increased in patients with IIM and its concentration correlates with the degree of disability. In patients with anti-SRP antibodies, levels of sST2 are exceptionally high.

Keywords

Idiopathic inflammatory myopathy · ST2 · IL-33 · Myositis

Introduction

IIM is usually associated with muscle inflammation leading to progressive weakness; however, also the skin and internal organs may be affected [1, 2]. The role of IL-33/ST2 (interleukin-33/suppression of tumorigenicity 2) pathway has been studied recently in various diseases including...
infectious, autoimmune, metabolic and degenerative conditions [3]. IL-33/ST2 signalling participates in inflammatory resolution, not only leading to tissue repair but also provoking fibrosis of potentially any internal organ [3]. After muscular injury, IL-33 regulates the accumulation of regulatory T cells [3]. Interaction of sST2 and macrophages can down-regulate pro-inflammatory cytokines [4]. IL-33 fulfills cardioprotective function, especially in response to myocardial stress, imposing an anti-hypertrophic effect due to blocking the influence of angiotensin II and phenylephrine on cardiac muscle, reducing fibrosis and enhancing cardiomyocytes survival [5, 6]. sST2, being a decoy a receptor for IL-33, suppress its pleiotropic impact on both innate and adaptive responses and has emerged as a novel prognostic biomarker of cardiac dysfunction [3].

The aim of the study was to evaluate the concentrations of IL-33 and sST2 in sera of patients with IIM, as well as its association with clinical manifestations, laboratory tests and autoantibodies profile.

Patients and methods

Sixteen (16) consecutive patients with IIM (polymyositis, dermatomyositis, antisynthetase syndrome, myositis with overlapping scleroderma), being hospitalized in the Department of Rheumatology between 2018 and 2019 and agreed to participate, were recruited. Diagnosis were based on the Peter and Bohan criteria [7, 8]. All the patients included in the study group met also the EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups—seven patients had define IIM, nine probable IIM [9]. Seventeen (17) age- and gender-matched healthy subjects were enrolled as the control group. Exclusion criteria for the control group included any autoimmune, musculoskeletal or cardiovascular diseases.

9 ml of peripheral blood were collected from both patients and healthy controls, serum samples were stored for subsequent IL-33 and sST2 analysis. Levels of IL-33 and sST2 were measured by commercially available enzyme-linked immunosorbsent assays (ELISA) in serum samples. For sST2 estimation, we used The Human ST2 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb219434) and for the measurement of IL-33 Human IL-33 ELISA Kit (Biorbyt Ltd., Cambridge, United Kingdom, product number: orb390944). For sST2 analysis, the samples were diluted 3:100 (serum:diluent). No samples dilutions were made for IL-33 measurement. Assay procedures were followed according to the manuals provided by the manufacturer (protocols with an overnight incubation at 4 °C). Optical density was measured by plate reader at 450 nm and concentrations were automatically interpolated form the standard curve. The concentration of sST2 obtained in diluted-sera were multiplied by the dilution factor to determine the concentrations in the non-diluted samples. All the results concerning sST2 in the result section are presented after multiplication by the dilution factor. During hospitalization, patients were asked to fill in the questionnaire prepared by the authors in Polish language (native language of the participants), concerning symptoms and concomitant diseases. Degree of myalgia, muscle weakness, fatigue and tolerance of physical activity were self-assessed by the patients in 0–10 scale, where 0 indicated no presence of evaluated feature and 10 the highest possible intensity that impairs daily activities. Patients were also asked to assess their physical functioning by filling in the Short 2-page Health Assessment Questionnaire, referred as the Health Assessment Questionnaire-Disability Index (HAQ-DI, Polish translation). Standard and Alternative Disability Indexes (SDI, ADI) were counted according to the instructions contained in The Health Assessment Questionnaire (HAQ) disability index (DI) of the clinical health assessment questionnaire (version 96.4) [10]. Results of laboratory tests such as complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatine kinase (CK) and its muscle-brain isoform (CK-MB), myoglobin, N-terminal pro-brain peptide (NT-proBNP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were obtained retrospectively from medical documentation if performed during the same hospitalization as serum samples collection. Titres and types of antinuclear antibodies (ANA) were also obtained retrospectively. Cardiac troponin T and I were assessed in the blood samples collected from the patients.

Data were analysed with STATISTICA 13.1 software. The normality of data was tested by Shapiro–Wilk test. Concentration of sST2 and IL-33 was compared between patients with IIM and healthy controls with U Mann–Whitney test. Associations between clinical symptoms, comorbidities or ANA subtypes with sST2 and IL-33 concentrations were evaluated with U Mann–Whitney tests (for symptoms and comorbidities only if they were present in at least four patients). Linear regressions were performed to evaluate the influence of the laboratory parameters, myalgia, muscle weakness, fatigue, tolerance of physical activity and degree of disability on sST2 and IL-33 levels.

The procedures followed were in accordance with the ethical standards and were approved by the responsible bioethical committee on human experimentation (Bioethical Committee of the Medical University of Lodz, Poland, date of approval: 15.05.2018, reference number: RNN/173/18/KE). All patients gave written, informed consent for participation in the study.
Results

Clinical characteristics of the patients enrolled for the study as well results of laboratory tests are presented in Table 1. Half of the patients declared exertional dyspnoea or episodes of chest pounding/irregular heartbeat occurring currently or in the past after the diagnosis of IIM. Most common comorbidities in patients with IIM included hypertension, thyroid disorders, interstitial lung disease and hypercholesterolemia/atherosclerosis. 10 patients filled in the Short 2-page Health Assessment Questionnaire. According to SDI, 30% fulfilled the criteria of mild-to-moderate disability, 40% of moderate-to-severe disability and 30% of severe-to-very severe disability.

All the 16 patients were ANA-positive, specific autoantibodies were detected in 15 patients (93.75%). 11 out of 16 patients included in the study group had myositis-specific autoantibodies, four patients had only myositis-associated autoantibodies. In one patient (ANA positive), no specific autoantibodies were detected. The most common subtype of ANA was anti-Ro52 in 62.50% of patients, followed by anti-Jo1 in 50% of cases, anti-PM-Scl in 25%, anti-SRP in 18.75% and AMA-M2 in 18.75% (Table 1). Single cases of anti-Ku, anti-HI and anti-centromere antibodies were detected.

Mean values of complete blood count, ESR and CRP in patients remained within normal limit, whereas levels of CK, CK-MB, myoglobin, NT-proBNP, AST and ALT were elevated (Table 1). Noteworthy, 87% out of 15 patients with IIM presented elevated levels of troponin T, whereas troponin I was increased only in 20% of them (Table 1).

Concentrations of sST2 in sera ranged from 13.12 to 68.67 ng/ml in patients with IIM and from 15.24 to 32.40 ng/ml in healthy controls. Concentrations of sST2 were significantly higher in IIM group than in healthy subjects (median sST2 in IIM 26.51 ng/ml vs median sST2 in healthy controls 21.39; p = 0.03). Concentrations of IL-33 in sera ranged from below the detection limit to 956.35 pg/ml. In half of the patients with IIM and half of the control group concentrations of IL-33 did not exceed the detection limit of 15.6 pg/ml. No significant difference was observed in serum concentrations of IL-33 between patients with IIM and healthy controls (respectively, median 0.4019; < 15.6 to 956.35 in IIM group vs median 1.5404; < 15.6 to 1051.64 in control group; p = 0.8).

No significant difference was observed in concentrations of sST2 and IL-33 between patients with and without dyspnoea, chest pounding/irregular heartbeat and remaining clinical symptoms such as arthralgia, dysphonia, dysphagia, erythema. Comorbidities, degree of myalgia, muscle weakness, fatigue and tolerance of physical activity were not significantly associated with significantly higher concentrations of sST2 or IL-33. Anti-SRP-positive patients presented significantly higher concentrations of sST2 as compared to anti-SRP-negative patients (Fig. 1, mean value of 52.49 ± 16.57 ng/ml in anti-SRP-positive patients vs mean value of 28.33 ± 11.32 ng/ml in anti-SRP-negative patients; p = 0.04). In contrast, in patients with anti-Ro52 antibodies, sST2 concentrations were significantly lower than in anti-Ro52-negative patients (Fig. 1, mean value of 26.54 ± 12.05 ng/ml in anti-Ro52-positive patients vs mean value of 43.40 ± 15.09 ng/ml in anti-Ro52-negative patients; p = 0.02). Both ADI and SDI scores correlated with the sST2 concentrations (Fig. 2, respectively, r = 0.769; p = 0.01 for ADI and r = 0.764; p = 0.01 for SDI). Serum levels of sST2 and IL-33 did not correlate with the results of laboratory tests.

Discussion

To our knowledge, the role of IL-33/ST2 pathway in patients with IIM has been previously evaluated only in a single study [11]. Yuan et al. noted significantly higher levels of sST2 in dermatomyositis/polymyositis (DM/PM) patients as compared to healthy controls [11]. This observation remains in line with the results of our study, as we also obtained significantly higher concentrations of sST2 in patients with IIM than in the control group. Authors observed also a strong positive correlation between sST2 levels and global VAS score [11], which partially corresponds with our results, as we demonstrated a positive correlation between sST2 levels and degree of disability assessed with HAQ-DI. Contrary to our study, in the research conducted by Yuan et al., serum sST2 levels correlated with CRP, CK and LDH [11]. In the study by Yuan et al. concentrations of IL-33 in DM/PM patients were not significantly higher than in the control group [11]. This observation also corresponds with our results, yet it need to be highlighted than in our study half of the patients had IL-33 concentrations below the detection limit.

Half of the patients from our study group experienced palpitations and exertional dyspnoea. This corresponds with the results conducted by Diederichsen et al. on the larger study group, in which 57% of IIM patients complained of dyspnoea and 34% reported palpitations [12]. In our study, majority of patients with IIM presented elevated levels of troponin T, whereas troponin I was increased only in 20% of them. However, in patients with myositis coexistence of cardiac and muscular lesions may distort the results of laboratory tests. Elevated concentrations of cardiac troponin T (cTnT) and CK-MB may result not only from the injury of cardiomyocytes but also from regenerating skeletal myocytes [13–15]. High concentrations of cardiac cTnT might be associated with severe course of myopathy [16]. Despite
| Table 1 | Clinical characteristics of the patients and healthy controls recruited for the study |
|---------|----------------------------------------------------------------------------------|
|         | IIM N = 16 [median; min–max] | Control group N = 17 [median; min–max] | p       |
| Demographical data | | | > 0.05 |
| Gender | F = 8; M = 8 | F = 8; M = 9 | > 0.05 |
| Age (years) | 59.50; 25–76 | 50.00; 25–65 | > 0.05 |
| Disease duration (months) | 9.5; 1–52 | – | – |
| Clinical symptoms present at any time after diagnosis [n (%)] | | | |
| Arthralgia | 7 (43.75) | – | – |
| Dysphagia | 6 (37.5) | – | – |
| Dysphonia | 7 (43.75) | – | – |
| Erythema | 5 (31.25) | – | – |
| Gottron papules/sign | 3 (18.75) | – | – |
| Raynaud phenomenon | 2 (12.5) | – | – |
| Mechanic’s hands | 3 (18.75) | – | – |
| Dyspnoea at rest | 4 (25.00) | – | – |
| Exertional dyspnoea | 8 (50.00) | – | – |
| Chest pain | 2 (12.5) | – | – |
| Irregular heartbeat, chest pounding | 8 (50.00) | – | – |
| Dry cough | 3 (18.75) | – | – |
| Productive cough | 3 (18.75) | – | – |
| Fever | 2 (12.5) | – | – |
| VAS 0–10 | | | |
| Myalgia | 6.25; 0–10 (N=14) | – | – |
| Muscle weakness | 6.50; 0–10 (N=14) | – | – |
| Fatigue | 5.00; 0–9 (N=14) | – | – |
| Tolerance of physical activity | 7.00; 3–10 (N=13) | – | – |
| Health Assessment Questionnaire | | | |
| ADI | 1.06; 0.25–3.00 (N=10) | – | – |
| SDI | 1.25; 0.25–3.00 (N=10) | – | – |
| Most common comorbidities [n (%)] | Hypertension | 9 (56.25) | – | – |
Table 1 (continued)

| Test                                         | Norm                                      | Control group                        | p     |
|----------------------------------------------|-------------------------------------------|--------------------------------------|-------|
| Thyroid disorders                            |                                           | Control group                        | p     |
| Interstitial lung disease/unspec. interstitial lesions |                                           | Control group                        | p     |
| Hypercholesterolemia, atherosclerosis        |                                           | Control group                        | p     |
| Arrhythmia                                   |                                           | Control group                        | p     |
| Laboratory tests                             |                                           |                                      |       |
| Test                                         | Norm                                      |                                      |       |
| WBC ($\times 10^3/\mu l$)                    | 4.00–11.00                                | 8.18; 2.56–18.74 ($N = 15$)           | –     |
| RBC ($\times 10^6/\mu l$)                    | 4.20–6.10 ($M$)                           | 4.45; 3.71–5.68 ($N = 15$)            | –     |
|                                              | 3.80–5.40 ($F$)                           |                                      | –     |
| Hb (g/dl)                                    | 14.0–18.0 ($M$)                           | 13.60; 11.50–16.10 ($N = 15$)         | –     |
|                                              | 3.80–5.40 ($F$)                           |                                      | –     |
| PLT ($\times 10^3/\mu l$)                    | 150–400                                   | 282.00; 195.00–342.00 ($N = 15$)       | –     |
| ESR (mm/1 h)                                 | < 20                                      | 14.00; 4.00–38.00 ($N = 15$)           | –     |
| CRP (mg/l)                                   | 0.0–6.0                                   | 2.40; 0.40–23.70 ($N = 15$)            | –     |
| CK (U/l)                                     | 0.0–171.0                                 | 155.00; 20.00–25,463.0 ($N = 15$)      | –     |
| CK-MB (ng/ml)                                | < 4.94                                    | 6.01; 2.39–252.20 ($N = 7$)            | –     |
| Troponin T (ng/l)                            | < 14                                      | 65.56; 9.98–2061.00 ($N = 15$)         | –     |
| Troponin I (ng/l)                            | < 19                                      | 12.70; 1.80–451.10 ($N = 15$)          | –     |
| AST (U/l)                                    | 0.0–35.0                                  | 31.70; 13.60–671.50 ($N = 15$)         | –     |
| ALT (U/l)                                    | 0.0–45.0                                  | 38.50; 7.50–577.60 ($N = 15$)          | –     |
| Myoglobin (µg/l)                             | 23.0–72.0                                 | 142.00; 21.10–300.00 ($N = 12$)        | –     |
| NT-pro BNP (pg/ml)                           | < 125.0                                   | 329.00; 34.50–1412.00 ($N = 6$)        | –     |
| Subtypes of ANA ($n (%)$)                    |                                           |                                      |       |
| Jo-1                                         | 8 (50.00)                                 | –                                    | –     |
| Ro-52                                        | 10 (62.50)                                | –                                    | –     |
| SRP                                          | 3 (18.75)                                 | –                                    | –     |
| Pm-Scl                                       | 4 (25.00)                                 | –                                    | –     |
| AMA-M2                                       | 3 (18.75)                                 | –                                    | –     |
| 24 h ECG holter monitoring ($n (%)$)          |                                           |                                      |       |
| > 2000 supraventricular extrasystoles        | 2 (22.23) ($N = 9$)                       | –                                    | –     |
| > 200 ventricular extrasystoles              | 5 (55.56) ($N = 9$)                       | –                                    | –     |
| > 2000 ventricular extrasystoles             | 3 (33.34) ($N = 9$)                       | –                                    | –     |
| Soluble ST2 and IL-33 concentrations         |                                           |                                      |       |
| sST2 in serum sample (ng/ml)                 | 26.51; 13.12–68.67                       | 21.39; 15.24–32.40                    | < 0.05|
those facts, it is recommended to start the assessment in clinical practice with cTnT and evaluate cardiac troponin I (cTnI) in those who present increased concentrations of cTnT [14]. sST2 is associated with increased risk of death, heart failure or ventricular arrhythmia, as it reduces protective impact of IL-33 on myocardium [6, 17]. Yet, in our study, no correlations were found between IL-33, sST2 and clinical symptoms indicating cardiovascular involvement or biochemical markers of cardiac injury such as CK-MB, troponin T, troponin I or NT-proBNP. High concentrations of cardiac troponin T, that we observed in our study, may, therefore, be the result of severe muscle involvement. A larger study group could enable to state more reliable conclusions.

We analysed in detail the association between sST2 concentrations and different subtypes of ANA. Yuan et al. displayed no correlation between sST2 and anti-Jo-1 and anti-Mi2 antibodies [11]. Similarly, in our study, anti-Jo-1 and concentrations of sST2 did not correlate. However, we observed higher sST2 concentrations in anti-SRP-positive patients, what to our knowledge has not been stated before. Signal Recognition Particle (SRP) regulates transport of proteins through the endoplasmic reticulum membrane [18]. Antibodies targeting this protein-RNA complex are associated with poor response to treatment and might have been related to cardiac complication. In a study on 12 anti-SRP-positive PM patients 25% of them presented arrhythmia [19]. Case of anti-SRP-positive patient with IIM, who developed inflammatory cardiomyopathy was described [20]. In other case report, anti-SRP-positive myopathy led to myopericarditis [21]. In our study, all the three patients with anti-SRP antibodies declared irregular heartbeat/chest pounding. Two out of three patients declared high intensity of myalgia and minimal tolerance of physical activity. One anti-SRP-positive patient declared no myalgia at all. Furthermore, two anti-SRP-positive patients shared also comorbidities—both of them were diagnosed also with hypertension, ischemic heart disease, arrhythmia and heart failure. However, as no correlations were observed between sST2 concentration and intensity of myalgia or tolerance of physical activity, as well as between patients with and without clinical symptoms or particular comorbidities, observed difference could be related more to the presence of anti-SRP antibodies itself. Recently, anti-mitochondrial (AMA-M2)-positive phenotype was suggested to be related with cardiac involvement in IIM [22, 23], yet in our study we did not observe any correlation between AMA-M2 and concentration of sST2. However, we observed an increased level of troponin I in 3 out of 15 patients—1 of these patients was anti-SRP-positive, 1 AMA-M2-positive and 1 anti-Ku-positive.

We presented for the first time the association between anti-Ro52 antibodies and sST2 levels in patients with IIM. Anti-Ro52 is described as the most common myositis-associated antibody in adults with myositis, what corresponds

| Table 1 | **Laboratory tests** |
|---------|---------------------|
| **Test** | **Norm** |
| IL-33 in serum sample (ng/ml) | 0.4019; < 15.6–966.35 |
| N | 10 |
| sST2 in serum sample (ng/ml) | 1.5404; < 15.6–1051.64 (N = 10) |
| N | 10 |
| sST2 in synovial fluid (ng/ml) | > 0.05 |
| N | 10 |

IIM idiopathic inflammatory myopathy, ANA antinuclear antibodies, VAS visual analogue scale.
with our results [24]. Presence of anti-Ro antibodies in PM may be associated with conductive disturbances such as atrioventricular heart blocks and bundle branch blocks [25]. Anti-Ro52 antibodies are also associated with interstitial lung disease (ILD) and coexistence of anti-Jo-1 and anti-Ro52 with severe course of ILD [26]. In our study, 7 out of 16 patients had ILD and 85.71% of those with ILD were anti-Ro52 positive. The highest mRNA transcriptional content of sST2 was found in lungs, heart and brain tissue. Secretion of sST2 from myocytes and pneumoepithelial cells is enhanced by pro-inflammatory cytokines [4]. Surprisingly, in our study anti-Ro52-positive patients presented lower levels of sST2. Furthermore, sST2 concentrations in patients with ILD did not differ as compared to patients without ILD. Researchers have found that levels of sST2 mRNA transcription are higher in bronchial and alveolar epithelial cells as compared to lung fibroblasts, therefore, sST2 may be associated with the airway diseases rather than ILD [4].

The main limitation of our study, that could impact the results, is that study group was limited and highly heterogeneous as for the age of the patients, disease duration and disease activity, subtypes of antinuclear antibodies. Yet, IIM are rare disorders with the prevalence ranging from 2.4 to 33.8/100000 and our study was a single-centre observation with a short duration time [27]. Some of the subgroups of patients (for example anti-SRP-positive) consisted of only few patients, therefore, studies on larger number of patients are required to form reliable conclusions. Furthermore, results of laboratory tests as well as filled questionnaires (especially HAQ-DI) were not available for every patient enrolled for a study. Moreover, our study lack echocardiographic examination. According to literature, left ventricular diastolic dysfunction and echocardiographic lesions indicating diastolic impairment are frequently seen in patients with myositis [12, 28]. Therefore, we cannot exclude the possibility of missing features of cardiac involvement. A study on larger group with assessment of the echocardiographic lesions would be necessary to draw more definite conclusions.

**Conclusions**

Soluble ST2 is increased in patients with IIM and its concentration correlates with degree of disability. No correlations were found between IL-33 and sST2 concentrations and clinical symptoms or biochemical tests. sST2 concentrations may be associated with autoantibody profile as in patients with anti-SRP antibodies levels of sST2 are exceptionally high.

**Related congress abstracts**

1. Partial results of the study, concerning clinical symptoms, results of 24 hour ECG Holter monitoring and results of biochemical tests in some of the patients from the study group have been presented at the students’ conference: 57th Polish and 15th International
Compliance with ethical standards

Conflict of interest Author Aleksandra Opinc declares that she has no conflict of interest. Author Joanna Sarnik declares that she has no conflict of interest. Author Olga Brzezińska declares that she has no conflict of interest. Author Marcin Makowski declares that he has no conflict of interest. Author Joanna Makowska declares that she has no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Bioethical Committee of the Medical University of Lodz, Poland. Reference number: RNN/173/18/KE) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mandel DE, Malemud CJ, Askari AD (2017) Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis. Int J Mol Sci 18:1084. https://doi.org/10.3390/ijms18051084
2. Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14:269–278. https://doi.org/10.1038/nrrheum.2018.41
3. Liew FY, Girard JP, Turnquist HR (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16:676–689. https://doi.org/10.1038/nri.2016.95
4. Mildner M, Storka A, Lichtenauer M et al (2010) Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 87:769–777. https://doi.org/10.1093/cvr/cqv104
5. Pascual-Figal DA, Lax A, Perez-Martinez MT, del Carmen Asensio-Lopez M, Sanchez-Mas J, GREAT Network (2016) Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med 54:29–35. https://doi.org/10.1515/cclm-2015-0074
6. Ciccone MM, Cortese F, Gusualdo M et al (2013) A novel cardiac bio-marker: ST2; a review. Molecules 18:15314–15328. https://doi.org/10.3390/ions181215314
7. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347. https://doi.org/10.1056/NEJM197502132920706
8. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407. https://doi.org/10.1056/NEJM197502202920807
9. Lundberg IE, Tjarnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468
10. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145. https://doi.org/10.1002/art.1780230202
11. Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31:428–432 (PMID: 23485578)
12. Diederichsen LP, Simonsen JA, Diederichsen AC et al (2016) Cardiac abnormalities in adult patients with polymyositis or dermatomyositis as assessed by noninvasive modalities. Arthritis Care Res (Hoboken) 68:1012–1020. https://doi.org/10.1002/acr.22772
13. Chen F, Peng Y, Chen M (2018) Diagnostic approach to cardiac involvement in idiopathic inflammatory myopathies. Int Heart J 59:256–262. https://doi.org/10.1536/ihj.17-20466
14. Hughes M, Lilleker JB, Herrick AL, Chimney H (2015) Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low grade skeletal muscle disease activity. Ann Rheum Dis 74:795–798. https://doi.org/10.1136/annrheumdis-2014-20681267
15. Aggarwal R, Lebiedz-Odrobina D, Sinha A, Manadan A, Case JP (2009) Serum cardiac troponin T, but not troponin I, is elevated
in idiopathic inflammatory myopathies. J Rheumatol 36:2711–2714. https://doi.org/10.3899/jrheum.090956
16. Fisher C, Agrawal S, Wong WM, Fahie-Wilson M, Dasgupta B (2010) Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice. Clin Rheumatol 29:1107–1111. https://doi.org/10.1007/s10067-010-1511-6
17. Skali H, Gerwien R, Meyer TE, Snider JV, Solomon SD, Stolen CM (2016) Soluble ST2 and risk of arrhythmias, heart failure, or death in patients with mildly symptomatic heart failure: results from MADIT-CRT. J Cardiovasc Transl Res 9:421–428. https://doi.org/10.1007/s12265-016-9713-1
18. Nakashima R (2018) Clinical significance of myositis-specific autoantibodies. Immunol Med 4:103–112. https://doi.org/10.1080/25785826.2018.1531188
19. Gupta R, Wayangankar SA, Targoff IN, Hennebry TA (2011) Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol 148:261–270. https://doi.org/10.1016/j.ijcard.2010.08.013
20. Takeguchi-Kikuchi S, Hayasaka T, Katayama T et al (2019) Anti-signal recognition particle antibody-positive necrotizing myopathy with secondary cardiomyopathy: the first myocardial biopsy-and multimodal imaging-proven case. Intern Med 58:3189–3194. https://doi.org/10.2169/internalmedicine.2564-18
21. Tanaka M, Gamou N, Shizukawa H, Tsuda E, Shimohama S (2016) Myopericarditis in a case of anti-signal recognition particle (anti-SRP) antibody-positive myopathy. Rinsho Shinkeigaku 56:862–865. https://doi.org/10.5692/clinicalneurol.cn-000916
22. Maeda MH, Tsuji S, Shimizu J (2012) Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 13:1767–1777. https://doi.org/10.1093/brain/aws106
23. Alhayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L (2018) Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47:552–556. https://doi.org/10.1016/j.semarthritis.2017.06.004
24. Sabbagh S, Pinal-Fernandez I, Kishi T et al (2019) Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2018-215004
25. Behan WM, Behan PO, Gairns J (1987) Cardiac damage in polymyositis associated with antibodies to tissue ribonucleoproteins. Br Heart J 5:176–180. https://doi.org/10.1136/hrt.57.2.176
26. Vánacs A, Csípő I, Németh J et al (2009) Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29:989. https://doi.org/10.1007/s00296-009-0884-9
27. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54:50–63. https://doi.org/10.1093/rheumatology/keu289
28. Wang H, Liu HX, Wang YL, Yu XQ, Chen XX, Cai L (2014) Left ventricular diastolic dysfunction in patients with dermatomyositis without clinically evident cardiovascular disease. J Rheumatol 41:495–500. https://doi.org/10.3899/jrheum.130346

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.